Novo shelves German Tresiba launch
Novo Nordisk will not be launching its newest diabetes drug, Tresiba, in Germany. The risk of having to pull the product later on is simply to great at the moment.
by Stefan Singh Kailay
It is the biggest market in Europe. And Tresiba has been hailed as the challenger set to fight it out with the world’s best selling diabetes product, Lantus, from French company Sanofi.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
